This study is completed in Belgium, in Argentina, in Bulgaria, .... It is testing esketamine for depression.
DepressionDrugFrom 18 Years to 74 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Esketamine may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Esketamine, attend study visits with the research team. The registry lists locations in Argentina, in Belgium, and in Bulgaria.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: April 26, 2021
Recruitment status
Completed
Enrollment listed in the registry
183
Sponsor
Janssen-Cilag Ltd.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Belgium, Argentina, Bulgaria, ...
Age range
From 18 Years to 74 Years
Official registry ID
NCT04829318
Official title
Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego
Lodz
Site status: Not listed — confirm with the team
SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych
Lodz
Site status: Not listed — confirm with the team
Osrodek Badan Klinicznych CLINSANTE S C
Torun
Site status: Not listed — confirm with the team
South Africa · 2 sites
Cape Town Clinical Research Centre
Cape Town
Site status: Not listed — confirm with the team
Gert Bosch Pretoria South Africa
Pretoria
Site status: Not listed — confirm with the team
South Korea · 2 sites
Severance Hospital Yonsei University Health System
Seoul
Site status: Not listed — confirm with the team
Samsung Medical Center
Seoul
Site status: Not listed — confirm with the team
Taiwan · 4 sites
Changhua Christian Hospital
Changhua
Site status: Not listed — confirm with the team
National Taiwan University Hospital
Taipei
Site status: Not listed — confirm with the team
Taipei Veterans General Hospital
Taipei
Site status: Not listed — confirm with the team
Chang Gung Memorial Hospital
Taoyuan
Site status: Not listed — confirm with the team
Türkiye · 3 sites
Hacettepe University Medical Faculty
Ankara
Site status: Not listed — confirm with the team
Erenkoy Mental Health Hospital
Istanbul
Site status: Not listed — confirm with the team
Liv Hospital
Samsun
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04829318. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Esketamine, SSRI/SNRI. Phase 4 studies usually happen after treatment approval, to monitor real-world use.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 74 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Cilag Ltd., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
